“Bjorn has profoundly influenced where I spend my energy, leading to notable improvements in both personal and business aspects. Through his coaching, I have experienced growth and development. His insightful advice and candid approach enabled me to identify barriers and take immediate actions.
Bjorn fosters accountability and sustains the momentum. I have found Bjorn to be honest and trustworthy. The outcomes of our collaboration have undeniably resulted in enhanced personal and professional success."
President,
North America Operations,
Xellia Pharmaceuticals Chicago
Business Culture Awards
On behalf of the project team, Bjørn Thonvold received as VP People & Organization Xellia Pharmaceuticals, the Business Culture Award 2019
He has since been on a part of the Awards judging panel.
Business Cases
1
Culture
Led the work of establishing a purpose, values and leadership promise in a fast-growing pharma company. The company hired more than 1000 employees in this period, and at the same time the leadership index went from 69 to 78%, cooperation went from 72 to 82%, and engagement went from 82 to 85%. Revenue had an increase of 65% and EBITDA more than doubled.
2
Leadership
Established a global team of 30 skilled HR professionals in a multicultural context and complex company footprint. The Employee survey showed 100% positive answers in the HR team to the questions if this is a great place to work, if their leaders empower them and make them shine and if they feel proud to work here
3
Growth Mindset
Reimagining the performance mgmt. process from being entirely centered around KPI’s and rating, to focus on a “growth mindset” and “Discovery Conversations” The objective being increased innovation and adaptability to change.
The paradigm shift included change mgmt., system adaptation, knowledge transfer, skill building, as well as cultivation of a “growth mindset”
4
Factory shut down
Led the development of a people strategy in response to a variety of business challenges, such as implementing a commercial model and organization in North America, prepare and launch a portfolio of innovative value added anti-infective’s, expand the capacity in the U.S. through an aseptic injectable facility in Cleveland and restructure in to two Business Units.